{"id":"W2970542184","doi":"10.3747/co.26.5137","title":"Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; University of Ottawa; Calgary Laboratory Services; Saskatchewan Health; Saskatchewan Health Authority; Queen Elizabeth II Health Sciences Centre; University of British Columbia; Institut universitaire de cardiologie et de pneumologie de Québec; University of Manitoba; St. Joseph’s Healthcare Hamilton; University of Calgary; Princess Margaret Cancer Centre; Alberta Cancer Foundation; Jewish General Hospital; University of Alberta; University of Saskatchewan; Université de Montréal; Dalhousie University; Canadian Red Cross Society","funders":"","keywords":"Crizotinib; ROS1; Medicine; Lung cancer; Oncology; Adenocarcinoma; Cancer research; Internal medicine; Clinical trial; Targeted therapy; Cancer; Tyrosine kinase; Tyrosine-kinase inhibitor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002992422,0.000700432,0.001344789,0.001438417,0.001073498,0.00241242,0.001514102,0.001870706,0.006388765],"category_scores_gemma":[0.003548292,0.0002388168,0.0006806666,0.002333479,0.001237565,0.0010848,0.0008277502,0.003893187,0.001356373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02461136,"about_ca_system_score_gemma":0.03781661,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5917823,"about_ca_topic_score_gemma":0.7876742,"domain_scores_codex":[0.9989491,0.0001373926,0.00008510437,0.0001326007,0.0004692052,0.0002266266],"domain_scores_gemma":[0.9951293,0.0003440542,0.0002814837,0.00005742977,0.003314421,0.0008733355],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.001397198,0.0002007406,0.002201476,0.002711369,0.0002048416,0.0006448349,0.000357944,0.0007109336,0.003807468,0.0155623,0.2969611,0.6752398],"study_design_scores_gemma":[0.0006883639,0.0005856611,0.007428083,0.002861558,0.0002699569,0.0007556367,0.0002152469,0.0004621884,0.0005918596,0.00206563,0.9840139,0.0000619186],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.004082466,0.8545617,0.0004916288,0.1146179,0.002328439,0.00006047775,0.0006987398,0.00007447281,0.02308406],"genre_scores_gemma":[0.038638,0.9293156,0.001673869,0.01830998,0.002789464,0.0000638932,0.0006433359,0.00004501669,0.008520927],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.4082177,"threshold_uncertainty_score":0.8212435,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02074937266872609,"score_gpt":0.3935389615663598,"score_spread":0.3727895888976336,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}